Generics in the United States
Generics in the United States
SUMMARY
Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The US generics market had total revenues of $108.9bn in 2019, representing a compound annual growth rate (CAGR) of 3.8% between 2015 and 2019.
- Market consumption volume increased with a CAGR of 0.8% between 2015 and 2019, to reach a total of 92.7% in 2019.
- With the lack of a national healthcare system in the US, the government cannot always secure low prices for medication.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume
- What was the size of the United States generics market by value in 2019?
- What will be the size of the United States generics market in 2024?
- What factors are affecting the strength of competition in the United States generics market?
- How has the market performed over the last five years?
- How large is the United States’s generics market in relation to its regional counterparts?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Pfizer Inc.
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: United States generics market value: $ billion, 2015-19
Table 2: United States generics market volume: % of total pharma, 2015-19
Table 3: United States generics market geography segmentation: $ billion, 2019
Table 4: United States generics market value forecast: $ billion, 2019-24
Table 5: United States generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: United States size of population (million), 2015-19
Table 17: United States gdp (constant 2005 prices, $ billion), 2015-19
Table 18: United States gdp (current prices, $ billion), 2015-19
Table 19: United States inflation, 2015-19
Table 20: United States consumer price index (absolute), 2015-19
Table 21: United States exchange rate, 2015-19
Table 1: United States generics market value: $ billion, 2015-19
Table 2: United States generics market volume: % of total pharma, 2015-19
Table 3: United States generics market geography segmentation: $ billion, 2019
Table 4: United States generics market value forecast: $ billion, 2019-24
Table 5: United States generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: United States size of population (million), 2015-19
Table 17: United States gdp (constant 2005 prices, $ billion), 2015-19
Table 18: United States gdp (current prices, $ billion), 2015-19
Table 19: United States inflation, 2015-19
Table 20: United States consumer price index (absolute), 2015-19
Table 21: United States exchange rate, 2015-19
LIST OF FIGURES
Figure 1: United States generics market value: $ billion, 2015-19
Figure 2: United States generics market volume: % of total pharma, 2015-19
Figure 3: United States generics market geography segmentation: % share, by value, 2019
Figure 4: United States generics market value forecast: $ billion, 2019-24
Figure 5: United States generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in the United States, 2019
Figure 7: Drivers of buyer power in the generics market in the United States, 2019
Figure 8: Drivers of supplier power in the generics market in the United States, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2019
Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2019
Figure 1: United States generics market value: $ billion, 2015-19
Figure 2: United States generics market volume: % of total pharma, 2015-19
Figure 3: United States generics market geography segmentation: % share, by value, 2019
Figure 4: United States generics market value forecast: $ billion, 2019-24
Figure 5: United States generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in the United States, 2019
Figure 7: Drivers of buyer power in the generics market in the United States, 2019
Figure 8: Drivers of supplier power in the generics market in the United States, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2019
Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2019